Dexcom reported $4.97B of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.97B (to Q2 2026). Net Income: $1000M, trailing twelve months to Q2 2026. Free Cash Flow: $1.41B, trailing twelve months to Q2 2026. Op Margin: 23%, trailing twelve months to Q2 2026.

DXCMDexcom

HealthcareUSD

$88.96

$54.8452 weeks$92.35

DXCM as reported

Dexcom reported $4.97B of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed.

$4.97B

Revenue, trailing twelve months · to Q2 2026 · +16% against the twelve months before

Net Income: $1000M
Net Income · +75% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $1.41B
Free Cash Flow · +146% year on year · trailing twelve months to Q2 2026
Op Margin: 23%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for DXCM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.97B	+16%	Q2 2026
Net Income	$1000M	+75%	Q2 2026
EPS	$2.52	+75%	Q2 2026
Gross Margin	62%	n/a	Q2 2026
Op Margin	23%	n/a	Q2 2026
Net Margin	20%	n/a	Q2 2026
ROE	32%	n/a	Q2 2026
ROA	13%	n/a	Q2 2026
ROIC	23%	n/a	Q3 2018 · 31 quarters behind
Free Cash Flow	$1.41B	+146%	Q2 2026
P/E	35.3	n/a	today